Cyberonics Inc (CYBX) 57.03 $CYBX
Cyberonics To Report Fiscal Year 2015 Third Quarter Results And Host Webcast And Conference Call On February 26, 2015
PR Newswire - Mon Feb 09, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the third quarter ended January 23, 2015 on Thursday, February 26, 2015 before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
CYBX: 57.03 (+0.26)
Global Neurosurgery Market 2015-2019 with Codman & Shurtleff, Integra LifeSciences, Medtronic & Stryker Dominating
M2 - Sat Jan 31, 1:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/6w2b7h/global) has announced the addition of the "Global Neurosurgery Market 2015-2019" report to their offering. The Global Neurosurgery market to grow at a CAGR of 11.71% over the period 2014-2019 Neurosurgery is a complex surgical procedure that involves diagnosis, treatment, and rehabilitation of disorders affecting any region of the nervous system. Some of the common neurosurgeries are endovascular neurosurgery, stereotactic neurosurgery, oncological neurosurgery, craniotomy, and neuroendoscopy. These surgeries are performed to treat neurological disorders, tumors, trauma, and injuries. The devices used to perform neurosurgeries are neurosurgical devices. One major trend upcoming in this market is the increased adoption of neurostimulators to treat migraines, chronic pain, epilepsy, post-cancer therapy pain, lower back pain, and Parkinson's disease. According to the report, a major factor driving this market is the increase in the prevalence of neurological disorders. These disorders include Alzheimer's disease, Parkinson's disease, stroke, migraine, depression, angina, obsessive-compulsive disorder, multiple sclerosis, neurological infections, and brain tumors. Further, the report states that the high cost of the equipment required for neurosurgery hinders its adoption by hospitals and other healthcare facilities. High installation costs and lack of reimbursement from insurance companies add to the up?front capital expenditure of hospitals. Key Vendors - Codman & Shurtleff - Integra LifeSciences - Medtronic - Stryker Other Prominent Vendors - Afferent - B. Braun - Boston Scientific - BrainLab - Cyberkinetics Neurotechnology Systems - Cyberonics - Elekta - Karl Storz - Micromar - Neuros Medical - NeuroVista - Scopis - SPR Therapeutics - St. Jude Medical - Synapse Biomedical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6w2b7h/global
BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), CYBX: 57.03 (+0.26)
Insider Trading Alert - MAIN, MKSI And CYBX Traded By Insiders
at The Street - Tue Jan 27, 9:30AM CST
Stocks with insider trader activity include MAIN, MKSI and CYBX
MAIN: 30.82 (+0.23), MKSI: 35.56 (-0.25), CYBX: 57.03 (+0.26)
PetMed (PETS) Earnings Miss, Revenues Top Estimates in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 8:10AM CST
PetMed Express (PETS), reported adjusted earnings per share (EPS) of 24 cents in the third quarter of fiscal 2015.
PETS: 15.57 (-0.05), EW: 134.23 (+1.89), HOLX: 30.46 (+0.21), CYBX: 57.03 (+0.26)
Hologic Upped to Buy on Sustained Growth, Strong Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 1:20PM CST
On Jan 19, Zacks Investment Research upgraded Hologic Inc. (HOLX) to a Zacks Rank #2 (Buy).
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), HOLX: 30.46 (+0.21), CYBX: 57.03 (+0.26)
The World Market for Neurostimulation Devices with Special Coverage on the U.S. and European Markets
M2 - Tue Jan 20, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/sp7rzc/the_world_market) has announced the addition of the "The World Market for Neurostimulation Devices (TENS, Carotid Sinus Nerve, Cochlear Implant, Deep Brain, Gastric Electrical, Phrenic Nerve, Sacral Nerve, Spinal Cord, Vagus Nerve, TMS, TNS and Other Stimulation Devices)" report to their offering. Numerous treatment techniques and devices apply therapeutic energy to selected areas of the body. Most act on nerves and muscles, and many use electrical stimulation. Such electrical techniques are variously referred to as neurostimulation, or neuromodulationthese two words refer to essentially the same group of techniques. Market numbers discussed in this report are focused on the global neurostimulation device market with special coverage on the U.S. and European markets. All sales are displayed at the manufacturers' level in U.S. dollars. Rather than attempting to define and classify all of the varying electrostimulatory methods, this report groups technologies into basic categories based on application and complexity.Two general segments are discussed with various sub-segments included. The market was formulated by first calculating individual market segments within the global neurostimulation device market, i.e. deep brain stimulation, sacral nerve stimulation and spinal cord stimulation, using direct manufacturer data. These data were collected through interviews with industry participants and experts. Secondary methods were used to verify initial findings including, but not limited to, company literature, medical databases, insurance databases, pricing reports, government reports and databases and other key secondary resources. Key Topics Covered: - Executive Summary - Introduction To Electrostimulation And Neurostimulation Technologies - External Neurological Stimulation Devices - Implanted Neurological Stimulation Devices - Industry Trends And Issues - Demographics And Statistics - Current Trends In Aging Populations - Market Summary - Company Profiles, Products, And Strategies - American Imex - Amrex Electrotherapy Equipment - Bioness, Inc. - Boston Scientific, Inc - Cochlear, Ltd. - Cyberonics, Inc - Delsys, Inc 167 - DJO International - Dynatronics Corporation - Electromedical Products International (EPI) - Magstim Company, Ltd. - Medtronic, INC - Multi Radiance Medical, Inc - Neuronetics, Inc - Noraxon USA, Inc - Prizm Medical, Inc. - Rich-Mar Corporation - RS Medical - ST Jude Medical, Inc. For more information visit http://www.researchandmarkets.com/research/sp...rld_market
BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), DYNT: 3.36 (-0.21), CYBX: 57.03 (+0.26)
Cyberonics (CYBX) Now a Buy: Are You Considering? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 3:35PM CST
On Jan 14, 2015, Zacks Investment Research upgraded Cyberonics Inc. (CYBX).
ABMD: 60.39 (+0.46), HNSN: 1.05 (+0.02), EW: 134.23 (+1.89), CYBX: 57.03 (+0.26)
Hologic (HOLX) Impresses with Preliminary Q1 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 1:10PM CST
Hologic (HOLX) has announced preliminary revenue results for first quarter of fiscal 2015.
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), HOLX: 30.46 (+0.21), CYBX: 57.03 (+0.26)
Short Interest Makes 24% Move For CYBX
MarketNewsVideo.com - Tue Jan 13, 2:24PM CST
The most recent short interest data has been released by the NASDAQ for the 12/31/2014 settlement date, which shows a 511,575 share increase in total short interest for Cyberonics, Inc. , to 2,634,962, an increase of 24.09% since 12/15/2014.
CYBX: 57.03 (+0.26)
AOL and Gilead Sciences are big market movers
AP - Tue Jan 06, 5:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), K.TO: 3.51 (-0.22), CS: 23.65 (+0.23), BBEP: 7.85 (+0.32), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), CYBX: 57.03 (+0.26), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), KGC: 2.81 (-0.17), AOL: 41.78 (+1.22), CVEO: 3.87 (+0.15), EBIX: 23.80 (+0.30), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), VZ: 49.31 (-0.21), XOOM: 15.77 (+0.64)
Adverse Reimbursement Verdict for Cyberonics' VNS Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:20PM CST
Cyberonics Inc. (CYBX) recently announced that the Departmental Appeals Board has declined its appeal on a medical reimbursement decision.
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), ANGO: 18.78 (+0.18), CYBX: 57.03 (+0.26)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:35PM CST
CERS: 5.53 (+0.08), RICE: 19.13 (-0.22), ECR: 7.29 (+0.12), ANTH: 3.84 (+0.06), NERV: 4.68 (+0.09), AU: 12.33 (+0.36), JNUG: 30.90 (+1.14), WTI: 6.55 (+0.41), CYBX: 57.03 (+0.26), GST: 2.89 (unch)
Cyberonics Provides Update On Departmental Appeals Board Decision Regarding Coverage Of VNS Therapy® System In Treatment-Resistant Depression
PR Newswire - Mon Jan 05, 3:01PM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced the receipt of a decision from the Departmental Appeals Board (DAB) of the Department of Health and Human Services.
CYBX: 57.03 (+0.26)
Cyberonics: Whether You Suffer From Depression Or Not, Don't Miss Your Chance To Profit From It
Ken McGaha - at Seeking Alpha - Tue Dec 30, 3:59PM CST
CYBX: 57.03 (+0.26)
Cyberonics: VNS Therapy Strong, Reimbursement Woes Stay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 1:30PM CST
On Dec 29, we issued an updated research report on Cyberonics Inc. (CYBX).
GTXI: 0.60 (-0.08), ACOR: 36.14 (-0.51), AFFX: 11.45 (+0.02), CYBX: 57.03 (+0.26)
Cyberonics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Dec 22, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, in San Francisco.
JPM: 59.67 (+0.10), CYBX: 57.03 (+0.26)
Cyberonics Posts Positive Epilepsy Device Data, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:30PM CST
Cyberonics' (CYBX) AspireSR generator delivers programmed VNS therapy, along with the benefits of a new feature ??? Automatic Stimulation ??? which identifies seizures.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), EW: 134.23 (+1.89), CYBX: 57.03 (+0.26)
Cyberonics Reports Consistently Positive Results From The E-36 And E-37 Studies For VNS Therapy Delivered By AspireSR® Generator
PR Newswire - Mon Dec 08, 10:45AM CST
Cyberonics, Inc. (NASDAQ:CYBX), maker of the VNS Therapy® System implanted in more than 80,000 patients, announced new results from two multi-site clinical studies of the AspireSR generator, E-36 (NCT01325623) and E-37 (NCT01846741), at the AES Annual Meeting in Seattle, Washington. The AspireSR generator is currently investigational in the U.S. and not approved for commercial use. The AspireSR generator attained the CE Mark and is now available in an increasing number of European countries.
CYBX: 57.03 (+0.26)
Cyberonics Earnings Review: 18 Days after Announcement Shares Down 2.0% (CYBX)
Comtex SmarTrend(R) - Mon Dec 08, 6:59AM CST
Two weeks ago on November 20th, 2014 Cyberonics (NASDAQ:CYBX) reported earnings and analysts, on average, expected earnings of $0.58 on sales of $75.6 million. The company actually reported EPS of $0.63 on sales of $73.4 million, beating EPS estimates by $0.05 and missing revenue estimates by $2.2 million. Shares of Cyberonics have slipped from $55.01 to $53.89, representing a loss of 2.0%, since the company reported earnings 18 days ago.
CYBX: 57.03 (+0.26)
MRI Interventions Welcomes Seasoned Medical Device Executive Wendelin Maners as Its New Vice President, Marketing
GlobeNewswire - Thu Dec 04, 7:33AM CST
MRI Interventions, Inc. (OTCQB:MRIC) today announces the addition of medical device veteran Wendelin Maners in the role of Vice President, Marketing, as CEO-elect Frank Grillo solidifies his management team. As Vice President, Marketing, Ms. Maners will head all marketing activities and programs, as well as develop and lead internal and external training programs for the Company.
BSX: 14.98 (+0.24), CYBX: 57.03 (+0.26)
Cyberonics To Report Fiscal Year 2015 Third Quarter Results And Host Webcast And Conference Call On February 26, 2015
PR Newswire - Mon Feb 09, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the third quarter ended January 23, 2015 on Thursday, February 26, 2015 before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).
CYBX: 57.03 (+0.26)
Global Neurosurgery Market 2015-2019 with Codman & Shurtleff, Integra LifeSciences, Medtronic & Stryker Dominating
M2 - Sat Jan 31, 1:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/6w2b7h/global) has announced the addition of the "Global Neurosurgery Market 2015-2019" report to their offering. The Global Neurosurgery market to grow at a CAGR of 11.71% over the period 2014-2019 Neurosurgery is a complex surgical procedure that involves diagnosis, treatment, and rehabilitation of disorders affecting any region of the nervous system. Some of the common neurosurgeries are endovascular neurosurgery, stereotactic neurosurgery, oncological neurosurgery, craniotomy, and neuroendoscopy. These surgeries are performed to treat neurological disorders, tumors, trauma, and injuries. The devices used to perform neurosurgeries are neurosurgical devices. One major trend upcoming in this market is the increased adoption of neurostimulators to treat migraines, chronic pain, epilepsy, post-cancer therapy pain, lower back pain, and Parkinson's disease. According to the report, a major factor driving this market is the increase in the prevalence of neurological disorders. These disorders include Alzheimer's disease, Parkinson's disease, stroke, migraine, depression, angina, obsessive-compulsive disorder, multiple sclerosis, neurological infections, and brain tumors. Further, the report states that the high cost of the equipment required for neurosurgery hinders its adoption by hospitals and other healthcare facilities. High installation costs and lack of reimbursement from insurance companies add to the up?front capital expenditure of hospitals. Key Vendors - Codman & Shurtleff - Integra LifeSciences - Medtronic - Stryker Other Prominent Vendors - Afferent - B. Braun - Boston Scientific - BrainLab - Cyberkinetics Neurotechnology Systems - Cyberonics - Elekta - Karl Storz - Micromar - Neuros Medical - NeuroVista - Scopis - SPR Therapeutics - St. Jude Medical - Synapse Biomedical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6w2b7h/global
BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), CYBX: 57.03 (+0.26)
Insider Trading Alert - MAIN, MKSI And CYBX Traded By Insiders
at The Street - Tue Jan 27, 9:30AM CST
Stocks with insider trader activity include MAIN, MKSI and CYBX
MAIN: 30.82 (+0.23), MKSI: 35.56 (-0.25), CYBX: 57.03 (+0.26)
PetMed (PETS) Earnings Miss, Revenues Top Estimates in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 8:10AM CST
PetMed Express (PETS), reported adjusted earnings per share (EPS) of 24 cents in the third quarter of fiscal 2015.
PETS: 15.57 (-0.05), EW: 134.23 (+1.89), HOLX: 30.46 (+0.21), CYBX: 57.03 (+0.26)
Hologic Upped to Buy on Sustained Growth, Strong Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 1:20PM CST
On Jan 19, Zacks Investment Research upgraded Hologic Inc. (HOLX) to a Zacks Rank #2 (Buy).
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), HOLX: 30.46 (+0.21), CYBX: 57.03 (+0.26)
The World Market for Neurostimulation Devices with Special Coverage on the U.S. and European Markets
M2 - Tue Jan 20, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/sp7rzc/the_world_market) has announced the addition of the "The World Market for Neurostimulation Devices (TENS, Carotid Sinus Nerve, Cochlear Implant, Deep Brain, Gastric Electrical, Phrenic Nerve, Sacral Nerve, Spinal Cord, Vagus Nerve, TMS, TNS and Other Stimulation Devices)" report to their offering. Numerous treatment techniques and devices apply therapeutic energy to selected areas of the body. Most act on nerves and muscles, and many use electrical stimulation. Such electrical techniques are variously referred to as neurostimulation, or neuromodulationthese two words refer to essentially the same group of techniques. Market numbers discussed in this report are focused on the global neurostimulation device market with special coverage on the U.S. and European markets. All sales are displayed at the manufacturers' level in U.S. dollars. Rather than attempting to define and classify all of the varying electrostimulatory methods, this report groups technologies into basic categories based on application and complexity.Two general segments are discussed with various sub-segments included. The market was formulated by first calculating individual market segments within the global neurostimulation device market, i.e. deep brain stimulation, sacral nerve stimulation and spinal cord stimulation, using direct manufacturer data. These data were collected through interviews with industry participants and experts. Secondary methods were used to verify initial findings including, but not limited to, company literature, medical databases, insurance databases, pricing reports, government reports and databases and other key secondary resources. Key Topics Covered: - Executive Summary - Introduction To Electrostimulation And Neurostimulation Technologies - External Neurological Stimulation Devices - Implanted Neurological Stimulation Devices - Industry Trends And Issues - Demographics And Statistics - Current Trends In Aging Populations - Market Summary - Company Profiles, Products, And Strategies - American Imex - Amrex Electrotherapy Equipment - Bioness, Inc. - Boston Scientific, Inc - Cochlear, Ltd. - Cyberonics, Inc - Delsys, Inc 167 - DJO International - Dynatronics Corporation - Electromedical Products International (EPI) - Magstim Company, Ltd. - Medtronic, INC - Multi Radiance Medical, Inc - Neuronetics, Inc - Noraxon USA, Inc - Prizm Medical, Inc. - Rich-Mar Corporation - RS Medical - ST Jude Medical, Inc. For more information visit http://www.researchandmarkets.com/research/sp...rld_market
BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), DYNT: 3.36 (-0.21), CYBX: 57.03 (+0.26)
Cyberonics (CYBX) Now a Buy: Are You Considering? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 3:35PM CST
On Jan 14, 2015, Zacks Investment Research upgraded Cyberonics Inc. (CYBX).
ABMD: 60.39 (+0.46), HNSN: 1.05 (+0.02), EW: 134.23 (+1.89), CYBX: 57.03 (+0.26)
Hologic (HOLX) Impresses with Preliminary Q1 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 1:10PM CST
Hologic (HOLX) has announced preliminary revenue results for first quarter of fiscal 2015.
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), HOLX: 30.46 (+0.21), CYBX: 57.03 (+0.26)
Short Interest Makes 24% Move For CYBX
MarketNewsVideo.com - Tue Jan 13, 2:24PM CST
The most recent short interest data has been released by the NASDAQ for the 12/31/2014 settlement date, which shows a 511,575 share increase in total short interest for Cyberonics, Inc. , to 2,634,962, an increase of 24.09% since 12/15/2014.
CYBX: 57.03 (+0.26)
AOL and Gilead Sciences are big market movers
AP - Tue Jan 06, 5:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 16.30 (-0.06), K.TO: 3.51 (-0.22), CS: 23.65 (+0.23), BBEP: 7.85 (+0.32), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), CYBX: 57.03 (+0.26), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), KGC: 2.81 (-0.17), AOL: 41.78 (+1.22), CVEO: 3.87 (+0.15), EBIX: 23.80 (+0.30), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), VZ: 49.31 (-0.21), XOOM: 15.77 (+0.64)
Adverse Reimbursement Verdict for Cyberonics' VNS Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:20PM CST
Cyberonics Inc. (CYBX) recently announced that the Departmental Appeals Board has declined its appeal on a medical reimbursement decision.
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), ANGO: 18.78 (+0.18), CYBX: 57.03 (+0.26)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 4:35PM CST
CERS: 5.53 (+0.08), RICE: 19.13 (-0.22), ECR: 7.29 (+0.12), ANTH: 3.84 (+0.06), NERV: 4.68 (+0.09), AU: 12.33 (+0.36), JNUG: 30.90 (+1.14), WTI: 6.55 (+0.41), CYBX: 57.03 (+0.26), GST: 2.89 (unch)
Cyberonics Provides Update On Departmental Appeals Board Decision Regarding Coverage Of VNS Therapy® System In Treatment-Resistant Depression
PR Newswire - Mon Jan 05, 3:01PM CST
Cyberonics, Inc. (NASDAQ:CYBX) today announced the receipt of a decision from the Departmental Appeals Board (DAB) of the Department of Health and Human Services.
CYBX: 57.03 (+0.26)
Cyberonics: Whether You Suffer From Depression Or Not, Don't Miss Your Chance To Profit From It
Ken McGaha - at Seeking Alpha - Tue Dec 30, 3:59PM CST
CYBX: 57.03 (+0.26)
Cyberonics: VNS Therapy Strong, Reimbursement Woes Stay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 1:30PM CST
On Dec 29, we issued an updated research report on Cyberonics Inc. (CYBX).
GTXI: 0.60 (-0.08), ACOR: 36.14 (-0.51), AFFX: 11.45 (+0.02), CYBX: 57.03 (+0.26)
Cyberonics To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Dec 22, 8:00AM CST
Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, in San Francisco.
JPM: 59.67 (+0.10), CYBX: 57.03 (+0.26)
Cyberonics Posts Positive Epilepsy Device Data, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:30PM CST
Cyberonics' (CYBX) AspireSR generator delivers programmed VNS therapy, along with the benefits of a new feature ??? Automatic Stimulation ??? which identifies seizures.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), EW: 134.23 (+1.89), CYBX: 57.03 (+0.26)
Cyberonics Reports Consistently Positive Results From The E-36 And E-37 Studies For VNS Therapy Delivered By AspireSR® Generator
PR Newswire - Mon Dec 08, 10:45AM CST
Cyberonics, Inc. (NASDAQ:CYBX), maker of the VNS Therapy® System implanted in more than 80,000 patients, announced new results from two multi-site clinical studies of the AspireSR generator, E-36 (NCT01325623) and E-37 (NCT01846741), at the AES Annual Meeting in Seattle, Washington. The AspireSR generator is currently investigational in the U.S. and not approved for commercial use. The AspireSR generator attained the CE Mark and is now available in an increasing number of European countries.
CYBX: 57.03 (+0.26)
Cyberonics Earnings Review: 18 Days after Announcement Shares Down 2.0% (CYBX)
Comtex SmarTrend(R) - Mon Dec 08, 6:59AM CST
Two weeks ago on November 20th, 2014 Cyberonics (NASDAQ:CYBX) reported earnings and analysts, on average, expected earnings of $0.58 on sales of $75.6 million. The company actually reported EPS of $0.63 on sales of $73.4 million, beating EPS estimates by $0.05 and missing revenue estimates by $2.2 million. Shares of Cyberonics have slipped from $55.01 to $53.89, representing a loss of 2.0%, since the company reported earnings 18 days ago.
CYBX: 57.03 (+0.26)
MRI Interventions Welcomes Seasoned Medical Device Executive Wendelin Maners as Its New Vice President, Marketing
GlobeNewswire - Thu Dec 04, 7:33AM CST
MRI Interventions, Inc. (OTCQB:MRIC) today announces the addition of medical device veteran Wendelin Maners in the role of Vice President, Marketing, as CEO-elect Frank Grillo solidifies his management team. As Vice President, Marketing, Ms. Maners will head all marketing activities and programs, as well as develop and lead internal and external training programs for the Company.
BSX: 14.98 (+0.24), CYBX: 57.03 (+0.26)
